1st Jul 2019 14:42
(Alliance News) - Scancell Holdings PLC said on Monday it has been a "busy and productive" six months for the company.
The company said that active patient recruitment for the SCIB1 phase two trial is expected in the coming weeks.
Scancell said it is continuing to talk to both Ichor Medical Systems Inc and the US Food & Drug Administration in relation to TriGrid v2.0 device questions. The company said it awaits further feedback from the agency with regards to investigational new drug approval which is required to initiate the US arm of the study.
In addition, the company said it has made further progressing the Modi-1 phase 1/2 clinical trial, with formulation work "well underway" to produce the final product for clinical testing and initiation of the preclinical toxicity testing programme.
"It has been a busy and productive six months for Scancell. We were pleased to welcome Vulpes as a shareholder in June and their investment not only strengthens our cash position, but provides a ringing endorsement of Scancell's future potential," said Chief Executive Cliff Holloway.
Shares in the cancer treatment developer were up 6.2% at 7.17 pence on Monday.
Related Shares:
Scancell Holdings